{
    "nctId": "NCT06202118",
    "briefTitle": "A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.",
    "officialTitle": "A Pilot Feasibility and Safety Trial of Intratumoral Diffusing Alpha-emitter Radiation Therapy (DaRT) for the Treatment of Newly Diagnosed or Recurrent Breast Carcinoma in Frail or Elderly Patients.",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Recurrent Breast Cancer, Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Feasibility -DaRT seed placement",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed invasive breast tumor with no involvement of skin within 12 months.\n* Tumor size \u2264 4 centimeters in the longest diameter.\n* Tumor is not deemed as resectable with radical surgery or the patient does not wish to go through surgery\n* De-novo or recurrent lesions.\n* Single lesion per quadrant per subject.\n* Targeted lesion must be technically amenable for complete coverage (including margins) by the DaRT seeds.\n* Interstitial implant indication validated by multidisciplinary team.\n* ECOG Performance Status \u22643.\n* Life expectancy \u226512 months.\n* Women Age \u226565 or younger if unfit for standard of care.\n* Willing and have the ability to provide signed Informed Consent.\n* Blood tests values:\n\n  * Leucocytes \u22653000mm3,\n  * Absolute neutrophil count \u22651500mm3,\n  * Platelets \u2265100,000 mm3,\n  * Total bilirubin \u2264 1.5xULN,\n  * AST, SGOT, SGPT \u22642.5xULN, If Alkaline Phosphatase \u2264 4xULN, then transaminases are normal.\n  * Creatinine \u2264 2.0xULN.\n  * INR or Prothrombin time \u22641.5xULN\n\nExclusion Criteria:\n\n* T4 category with skin involvement.\n* Ductal carcinoma in situ.\n* Inflammatory breast carcinoma.\n* Longest tumor diameter \\>4 cm.\n* Patients with prior radiation to the same area within the past 6 months.\n* Has a known additional malignancy that is progressing or requires active treatment.\n* Patients undergoing immunosuppressive and/or systemic corticosteroid treatment except for steroid inhalations for treatment of asthma or lung disease\n* Subjects not willing to sign an informed consent.",
    "sex": "ALL",
    "minimumAge": "65 Years",
    "stdAges": "OLDER_ADULT"
}